ロード中...
Central pharmacodynamic activity of solanezumab in mild Alzheimer's disease dementia
INTRODUCTION: Solanezumab treatment was previously shown to significantly increase total (bound + unbound) cerebrospinal fluid (CSF) levels of amyloid β (Aβ)(1–40) and Aβ(1–42) in patients with mild to moderate Alzheimer's disease dementia yet did not produce meaningful cognitive effects. This...
保存先:
| 出版年: | Alzheimers Dement (N Y) |
|---|---|
| 主要な著者: | , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Elsevier
2018
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6258891/ https://ncbi.nlm.nih.gov/pubmed/30511011 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.trci.2018.10.001 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|